NeuBase Therapeutics, Inc.
NeuBase Therapeutics, Inc. (NBSE) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nbse · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
NeuBase Therapeutics, Inc.You NBSE | $1M | N/A | — | -$21.08 |
 ASLAN Pharmaceuticals Limited ASLN | $777M | N/A | — | -$10.75 |
 CohBar, Inc. CWBR | $1M | N/A | — | -$4.13 |
 Altamira Therapeutics Ltd. CYTO | $1M | N/A | — | $0.00 |
 Impel Pharmaceuticals Inc. IMPL | $1M | N/A | — | -$5.52 |
 9 Meters Biopharma, Inc. NMTRQ | $0M | N/A | — | — |
 OncoSec Medical Incorporated ONCSQ | $0M | N/A | — | -$19.13 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for NeuBase Therapeutics, Inc. (NBSE) measures how much investors pay for each dollar of the company's trailing earnings. NBSE's current PE ratio of N/A is calculated by dividing its stock price of $0.38 by its TTM earnings per share of -$21.08.
Frequently asked questions
NBSE pe ratio · 6 questionsNBSE's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.38 and TTM EPS of -$21.08. Data sourced from Financial Modeling Prep via NBSE's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · NeuBase Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09